US Bancorp DE Buys 368 Shares of LeMaitre Vascular, Inc. $LMAT

US Bancorp DE raised its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 36.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,390 shares of the medical instruments supplier’s stock after purchasing an additional 368 shares during the period. US Bancorp DE’s holdings in LeMaitre Vascular were worth $117,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vestcor Inc increased its position in shares of LeMaitre Vascular by 108.0% during the first quarter. Vestcor Inc now owns 3,079 shares of the medical instruments supplier’s stock worth $258,000 after acquiring an additional 1,599 shares in the last quarter. Federated Hermes Inc. increased its position in shares of LeMaitre Vascular by 1.3% during the first quarter. Federated Hermes Inc. now owns 39,504 shares of the medical instruments supplier’s stock worth $3,314,000 after acquiring an additional 518 shares in the last quarter. Cetera Investment Advisers increased its position in shares of LeMaitre Vascular by 209.6% during the first quarter. Cetera Investment Advisers now owns 8,522 shares of the medical instruments supplier’s stock worth $715,000 after acquiring an additional 5,769 shares in the last quarter. Avantax Advisory Services Inc. increased its position in shares of LeMaitre Vascular by 1.5% during the first quarter. Avantax Advisory Services Inc. now owns 15,035 shares of the medical instruments supplier’s stock worth $1,261,000 after acquiring an additional 229 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of LeMaitre Vascular during the first quarter worth about $728,000. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Stock Up 0.1%

LeMaitre Vascular stock opened at $95.91 on Monday. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The stock has a market cap of $2.17 billion, a PE ratio of 46.56, a price-to-earnings-growth ratio of 2.47 and a beta of 0.79. The firm’s 50-day simple moving average is $84.56 and its 200 day simple moving average is $86.34. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business had revenue of $63.15 million for the quarter, compared to analysts’ expectations of $62.48 million. During the same period in the previous year, the company earned $0.52 earnings per share. The firm’s revenue for the quarter was up 15.0% compared to the same quarter last year. Research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Thursday, August 21st. LeMaitre Vascular’s payout ratio is presently 38.83%.

Analysts Set New Price Targets

Several research firms have recently commented on LMAT. Barrington Research raised shares of LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $95.00 target price for the company in a research report on Wednesday, August 6th. Cantor Fitzgerald boosted their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $98.00.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 10,815 shares of the business’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.39, for a total value of $999,197.85. Following the transaction, the director directly owned 17,976 shares in the company, valued at $1,660,802.64. The trade was a 37.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bridget A. Ross sold 2,500 shares of the business’s stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $94.00, for a total transaction of $235,000.00. Following the completion of the transaction, the director owned 2,916 shares in the company, valued at approximately $274,104. The trade was a 46.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 125,214 shares of company stock valued at $11,654,560 in the last three months. Insiders own 9.50% of the company’s stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.